Potentials for the early prophylaxis of progression of nonalcoholic fatty liver disease in the practice of clinicists

In developed countries, the prevalence of non-alcoholic fatty liver disease (NAFLD) is 10-40%. Data from epidemiological studies indicate a steady increase in its frequency in the world. In a variety of regional and international recommendations for drug treatment, there is no uniform opinion on the efficacy and safety of the use of certain drugs in the NAFLD. The use of essential phospholipids (EPLs) in liver diseases, in particular NAFLD, is pathogenetically justified and proved in a number of clinical studies. EPLs, however, is an easily decomposable substance, because they can be involved in lipid peroxidation processes with an increase in the level of lipid peroxides, which are an active oxidants, and consequently enhance oxidative stress. The creation of a domestic combined hepatoprotector BAA Hepaguard Active became an effective solution of this problem. One capsule of Hepaguard Active contains 222 mg of EPLs, 93 mg of L-carnitine and 1.25 mg of tocopherol acetate (vitamin E). These biologically active substances act synergistically, providing membrane-protective, lipotropic, lipid-lowering, and hypocholesterolemic effects. The course effect of BAA Hepaguard Active is manifested in a decrease in the severity of steatosis, and in non-alcoholic steatohepatitis - in the reduction of necroinflammatory processes and liver fibrosis, and also contributes to the normalization of body weight, and lipid profile. BAA Hepaguard Active has a prebiotic effect, helps to reduce insulin resistance, and is well tolerated, which allows to recommend it for primary and secondary prevention of NAFLD.

non-alcoholic fatty liver disease, essential phospholipids, L-carnitine, vitamin E